Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

10.00 +0.48 (+5.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mind Medicine Mindmed Inc

< Previous 1 2 3 4 Next >
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
From MindMed
Via Business Wire
MindMed to Present at Upcoming May Medical Conferences
From MindMed
Via Business Wire
MindMed to Present at Upcoming April Medical Conferences
From Mind Medicine
Via Business Wire
Mind Science Targeting Big Brains and Portfolios
Via AB Newswire
MindMed Announces Voluntary Delisting from Cboe Canada
From MindMed
Via Business Wire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
From MindMed
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
From MindMed
Via Business Wire
MindMed Reports 2023 Financial Results and Business Updates
From MindMed
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
From MindMed
Via Business Wire
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
From MindMed
Via Business Wire
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
MindMed Announces Business Update and Anticipated Milestones for 2024
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
From Mind Medicine
Via Business Wire
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
From Mind Medicine
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
From Mind Medicine Inc.
Via Business Wire
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
From Mind Medicine Inc
Via Business Wire
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From MindMed
Via Business Wire
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
MindMed to Participate at September Investor Conferences
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
From Mind Medicine (MindMed) Inc
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.